Strong growth then a telemedicine-driven contraction — the EU's clearest regulatory-risk case study.
Poland legalised medical cannabis in 2017 within a restrictive commercial framework. The market grew strongly from 2022 to 2024, then contracted after the Ministry of Health restricted online consultations in November 2024. It remains import-reliant, with no domestic production yet.
